Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Food-dependent exercise-induced anaphylaxis

Foong, Ru-Xina,b,c,*; Giovannini, Mattiab,d,*; du Toit, Georgea,b,c

Current Opinion in Allergy and Clinical Immunology: June 2019 - Volume 19 - Issue 3 - p 224–228
doi: 10.1097/ACI.0000000000000531
FOOD ALLERGY: Edited by Alessandro Fiocchi and Motohiro Ebisawa

Purpose of review The following article provides an overview of food-dependent exercise-induced anaphylaxis (FD-EIAn). The review focuses on the epidemiology, pathophysiology, and clinical findings of FD-EIAn and details current practice in terms of the investigation, management, and treatment options available.

Recent findings The management of FD-EIAn has not changed significantly over the last few years and still requires careful investigation by an experienced clinician to ensure that the correct diagnosis is made and appropriate treatment is given. Although new therapies such as synthetic prostaglandin E1 analogs and IgE monoclonal antibodies have been trialed as treatment options for FD-EIAn, the mainstay of treatment remains the graded reintroduction to exercise in a supervised setting.

Summary FD-EIAn is a rare but serious condition that can have a significant impact on patients’ lives. This review aims to discuss new relevant research into this field to help guide clinicians in managing this condition.

aChildren's Allergy Service, Evelina London Children's Hospital, Guy's and St. Thomas’ NHS Foundation Trust

bPediatric Allergy Group, Department of Women and Children's Health, School of Life Course Sciences

cPeter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, United Kingdom

dAllergy Unit, Department of Pediatrics, Anna Meyer Children's Hospital, University of Florence, Florence, Italy

Correspondence to George du Toit, Children's Allergy Service, Evelina London Children's Hospital, Guy's and St. Thomas’ NHS Foundation Trust, London SE1 7EH, United Kingdom. Tel: +44 2071880145; e-mail:

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.